Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
R. J. Kelly, B. V. Landon, et al.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCESO1 trial
J. Qin, L. Xue, et al.
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial
T. Sonoda, Y. Umeda, et al.
